Authority
Contraindications to Metabolic & Bariatric Surgery
The following are general categories of contraindications and exclusions commonly considered in metabolic and bariatric surgery practice. Specific contraindications for MagDI-based procedures are determined by the surgical team in accordance with FDA labeling and clinical evaluation.
Written by MagnaMetabolic Editorial Team Medically reviewed by Ariel Ortiz, MD — Bariatric & Metabolic Surgery Last reviewed: June 7, 2026
Commonly considered contraindications
- Untreated severe psychiatric illness or active substance use disorder that would prevent safe peri-operative care or follow-up.
- Active malignancy where surgery would interfere with cancer treatment.
- Severe untreated cardiopulmonary disease that makes general anesthesia unsafe.
- Unwillingness or inability to commit to long-term follow-up, dietary changes, and supplementation as required.
- Pregnancy or plans for imminent pregnancy (timing of any bariatric surgery should be coordinated with the obstetric team).
- Anatomical findings that preclude safe anastomosis formation.
- Other patient-specific factors identified during medical, anesthetic, nutritional, and psychological evaluation.
This list is not exhaustive. Final eligibility must be determined by a qualified surgical and metabolic team after individual evaluation.
Evidence
Scientific References
Selected primary sources informing this page. External links open in a new tab; we do not control or endorse third-party content.
- ASMBSAmerican Society for Metabolic and Bariatric Surgery (ASMBS) and IFSO 2022 indications for metabolic and bariatric surgery.
- NIDDKNational Institute of Diabetes and Digestive and Kidney Diseases — Bariatric Surgery for Severe Obesity.
- FDAU.S. FDA — De Novo Classification DEN240013: MagDI System (Magnetic Duodeno-Ileostomy), De Novo marketing authorization granted July 2, 2024.
- FDAU.S. FDA — 510(k) Premarket Notification K242086: MagDI System (second generation), clearance granted October 24, 2024.